Stock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss

Stock Track

Mar 02

Urogen Pharma Ltd. (URGN) shares plummeted 5.94% during Monday's intraday trading session. The biotech company experienced significant selling pressure shortly after the market opened.

The sharp decline appears to be driven by the company's fourth-quarter earnings report, which missed analyst expectations on both earnings per share and revenue. Urogen reported a loss of 54 cents per share for the quarter ended December 31, exceeding the mean analyst estimate of a 50-cent loss. Revenue of $37.84 million also fell short of the $39.92 million consensus estimate, despite representing a 54% increase from the same period last year.

While the company separately announced a refinanced term loan agreement with Pharmakon Advisors that provides additional non-dilutive capital and extends the maturity profile, investors focused on the disappointing quarterly results. The earnings miss overshadowed the positive financing news, leading to the significant intraday price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1126458358"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126458358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126458358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126458358","market":"hk","top_or_hot":-1,"title":"Stock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss","media":"Stock Track","content":"<p>Urogen Pharma Ltd. (URGN) shares plummeted 5.94% during Monday's intraday trading session. The biotech company experienced significant selling pressure shortly after the market opened.</p><p>The sharp decline appears to be driven by the company's fourth-quarter earnings report, which missed analyst expectations on both earnings per share and revenue. Urogen reported a loss of 54 cents per share for the quarter ended December 31, exceeding the mean analyst estimate of a 50-cent loss. Revenue of $37.84 million also fell short of the $39.92 million consensus estimate, despite representing a 54% increase from the same period last year.</p><p>While the company separately announced a refinanced term loan agreement with Pharmakon Advisors that provides additional non-dilutive capital and extends the maturity profile, investors focused on the disappointing quarterly results. The earnings miss overshadowed the positive financing news, leading to the significant intraday price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Urogen Pharma Plummets 5.94% Intraday Following Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Urogen Pharma Ltd. (URGN) shares plummeted 5.94% during Monday's intraday trading session. The biotech company experienced significant selling pressure shortly after the market opened.</p><p>The sharp decline appears to be driven by the company's fourth-quarter earnings report, which missed analyst expectations on both earnings per share and revenue. Urogen reported a loss of 54 cents per share for the quarter ended December 31, exceeding the mean analyst estimate of a 50-cent loss. Revenue of $37.84 million also fell short of the $39.92 million consensus estimate, despite representing a 54% increase from the same period last year.</p><p>While the company separately announced a refinanced term loan agreement with Pharmakon Advisors that provides additional non-dilutive capital and extends the maturity profile, investors focused on the disappointing quarterly results. The earnings miss overshadowed the positive financing news, leading to the significant intraday price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"","article_id":"1126458358","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126458358","pubTimestamp":1772462169,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Urogen Pharma Ltd. (URGN) shares plummeted 5.94% during Monday's intraday trading session. The biotech company experienced significant selling pressure shortly after the market opened.The sharp...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|Urogen Pharma盘中暴跌5.94%因Q4盈利未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"Urogen Pharma Ltd. (URGN) shares plummeted 5.94% during Monday's intraday trading session. The biotech company experienced significant selling pressure shortly after the market opened.The sharp decline appears to be driven by the company's fourth-quarter earnings report, which missed analyst expectations on both earnings per share and revenue. Urogen reported a loss of 54 cents per share for the quarter ended December 31, exceeding the mean analyst estimate of a 50-cent loss. Revenue of $37.84 million also fell short of the $39.92 million consensus estimate, despite representing a 54% increase from the same period last year.While the company separately announced a refinanced term loan agreement with Pharmakon Advisors that provides additional non-dilutive capital and extends the maturity profile, investors focused on the disappointing quarterly results. The earnings miss overshadowed the positive financing news, leading to the significant intraday price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}